China
Africa
Explore chapters and articles related to this topic
Synthetic Cathinones and Related Fatalities in the United Kingdom
Published in Ornella Corazza, Andres Roman-Urrestarazu, Handbook of Novel Psychoactive Substances, 2018
John M. Corkery, Christine Goodair, Hugh Claridge
Some synthetic cathinones remain licenced for medicinal use. For instance, bupropion (Amfebutamone, Zyban, Wellbutrin), which is primarily used as an antidepressant and a smoking cessation aid, has also been used for recreational purposes because of its cocaine-like effects (McCormick, 2002; Vento et al., 2013). Pyrovalerone, structurally related to MDPV, because of its stimulant effects, has been used in the clinical treatment of lethargy and chronic fatigue (Gardos & Cole, 1971). It has also been employed as an appetite suppressant and anorectic in France and elsewhere. However, problems with abuse and dependence mean it has not often been prescribed in recent years (Deniker, Lôo, Cuche, & Roux, 1975). Pyrovalerone is covered by Schedule IV of the United Nations (UN) 1971 Convention on Psychotropic Substances. In the UK, it was controlled as a Class C drug under the Misuse of Drugs Act 1971, prior to the inclusion of additional cathinones, e.g., mephedrone, in April 2010. Amfepramone was also categorized as a Class C drug.
Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats
Published in Clinical Toxicology, 2018
Olof Beck, Matilda Bäckberg, Patrick Signell, Anders Helander
The pyrovalerone drugs comprise a group of phenylethylamine and cathinone derivatives many of which were originally developed as therapeutic drug candidates but later appeared on the NPS market [5]. Indeed the parent compound of this group, pyrovalerone, is a psychostimulant drug used in a pharmaceutical product in the 1960s for treatment of lethargy, fatigue and obesity [6]. Following reports of misuse, pyrovalerone was withdrawn from the market [7] and eventually banned as a narcotic substance by the WHO in 1971 [8].
Synthetic cathinones: an evolving class of new psychoactive substances
Published in Critical Reviews in Toxicology, 2019
João L. Gonçalves, Vera L. Alves, Joselin Aguiar, Helena M. Teixeira, José S. Câmara
Pyrovalerone is another cathinone derivative, which appeared in 1960s and was used in the treatment of chronic fatigue and as an appetite suppressant (Gardos and Cole 1971; Goldberg et al. 1973). However, a few years after its discovery, pyrovalerone was withdrawn from the market and scheduled as a controlled substance, after reports of its intravenous abuse by polydrug users (Deniker et al. 1975).